J&J’s Aciphex Feels The Burn As Rx PPI Market Growth Levels Off
This article was originally published in The Tan Sheet
Executive Summary
Domestic sales of Johnson & Johnson's Rx proton pump inhibitor Aciphex (rabeprazole 20 mg) were negatively affected by the launch of Procter & Gamble's Prilosec OTC, providing another example of the sluggish growth of the prescription PPI market